Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

634 ARTÍCULOS , VIENDO DEL 166 AL 180

Comparative efficacy and safety of pathway-targeted pharmacotherapies for Alzheimer's disease: A systematic review and network meta-analysis of phase III trials

Wu Y, Di Y, Wang H, Wang L, Zhang J, Zhang Y, Lyu D.

Ageing Res Rev. 2026 Aug;120:103216. doi: 10.1016/j.arr.2026.103216. Epub 2026 Jun 24.

Marine Lipids and Alzheimer's Disease: Biochemistry, Bioaccessibility/Bioavailability, Metabolism, and Health Effects

Gomes-Bispo A, Cardoso C, Afonso C, Lourenço HM, Pedro S, Moniz P, Bandarra NM.

Mar Drugs. 2026 Jun 3;24(6):197. doi: 10.3390/md24060197.

From Tradition to Translation: A Critical Appraisal of Bacopa monnieri for Neuroprotection from Preclinical and Clinical Perspectives and Challenges in Utilization

Olajide AT, Aunsorn S, Kehinde SA, Kaewmanee T, Chusri S.

Int J Mol Sci. 2026 Jun 17;27(12):5488. doi: 10.3390/ijms27125488.

Multitarget Actions of Pentacyclic Triterpenic Acids in Alzheimer's Disease: Mechanistic Insights

Sharma N, An SSA.

Molecules. 2026 Jun 9;31(12):2018. doi: 10.3390/molecules31122018.

Dual-target inhibitors based on BuChE: A review from medicinal chemistry perspective

Ren C, Wang X, Yao Y, Liang S, Liao W, Yao Z.

Eur J Med Chem. 2026 Nov 5;317:119081. doi: 10.1016/j.ejmech.2026.119081. Epub 2026 Jun 23.

Network meta-analysis of different traditional Chinese medicine therapies as adjuvant treatments for Alzheimer's disease

Li Z, Bai X, Li J, Geng W, Xing X, Liang J, Li J, Li J.

Complement Ther Clin Pract. 2026 Aug;64:102075. doi: 10.1016/j.ctcp.2026.102075. Epub 2026 Jun 25.

Rational design, synthesis, and biological evaluation of chalcone hybrids including benzoylpiperazin (phenylacetylpiperazin)-thiophene as anti- Alzheimer's agents

Lin Z, Hu L, Liu Y, Ning W, Wang S, Fu ZY, Guan L.

Bioorg Med Chem Lett. 2026 Nov;140:130716. doi: 10.1016/j.bmcl.2026.130716. Epub 2026 Jun 29.

What should convince a clinician of disease modification in Alzheimer's disease clinical trials?

Hazan J, Liu KY, Howard R.

Alzheimers Dement. 2026 Jul;22(7):e71643. doi: 10.1002/alz.71643.

HDAC11 as a potential therapeutic target for Alzheimer's disease

Zhang W, Wang Y, Tocci D, Wang C, Zhang C.

Drug Discov Today. 2026 Jul;31(4):104730. doi: 10.1016/j.drudis.2026.104730. Epub 2026 Jul 14.

Preclinical evidence for icariin in Alzheimer's disease: Methodological quality, efficacy, and mechanisms

Chen ML, Hao LY, Zhang ZH, Xu HF, Li HF, Wen L, Zheng GQ.

Ageing Res Rev. 2026 Oct;121:103228. doi: 10.1016/j.arr.2026.103228. Epub 2026 Jul 5.

Targeting Autophagy in Alzheimer's Disease: Role of the AMPK/mTOR Pathway and Drug Repurposing

Dubey A, Chaurasia A, Ansari Z, Kushwaha SK, Saraf I, Kashaw S, Swami R, Kushwah V.

Drug Dev Res. 2026 Aug;87(5):e70344. doi: 10.1002/ddr.70344.

A Narrative Review of Amyloid-β Monoclonal Antibodies for Alzheimer Disease: How Amyloid Species Engagement May Affect Clinical Outcomes

Caselli RJ, Geldmacher DS, Schilling TB.

Neurologist. 2026 Jul 1;31(4):129-135. doi: 10.1097/NRL.0000000000000679.

A nose-to-brain drug delivery system targeting mitochondrial dysfunction: application potential and future prospects of chitosan nanogels in Alzheimer's disease

Huang Q, Zuo Y, Xie Y, Liu Z, Wang L, Xu H, Yu M, Liu C.

Biomater Sci. 2026 Aug 11;14(16):4164-4196. doi: 10.1039/d6bm00624h.

Repurposing apremilast for alzheimer's disease: multitarget modulation of cAMP‑PI3K/Akt-GSK‑3β and NF‑κB signaling

Choudhary N, Rana S, Vashisht K, Sharma V, Bhatia V, Ashawat MS, Kushawaha SK.

Metab Brain Dis. 2026 Jul 11;41(1):163. doi: 10.1007/s11011-026-01906-9.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias